COVID-19 Clinical Resources and Pertinent Research
A regularly updated list of the most useful COVID-19 clinical resources, the most significant research publications, and reliable news. To contribute, click the plus button on the left. Short URL: bit.ly/C19Res

Pediatrics

  1. COVID-19 in Pediatric Patients
    1. A Clinical Pathway for Hospitalized Pediatric Patients with Initial SARS-CoV-2 Infection (Tx Algorithm)
    2. Factors Associated with Severe Pediatric SARS-CoV-2 Infection
    3. COVID-19 in Children: Initial Characterization of the Pediatric Disease
    4. National Trends of Cases of COVID-19 in Children Based on US State Health Department Data (Commentary)
    5. SARS-CoV-2 Clinical Syndromes and Predictors of Disease Severity in Hospitalized Children and Youth
    6. Assessment of 135,794 Pediatric Patients Tested for SARS-CoV-2 Across the United States
    7. Effect of the New SARS-CoV-2 Variant B.1.1.7 on Children and Young People
    8. A Significant Proportion of Pediatric COVID-19 Patients Appear to Develop Conjunctivitis
    9. A Proportion of Hospitalized Pediatric Patients with SARS-CoV-2 Appear to Develop Thrombotic Microangiopathy
    10. Age-Dependent ACE2 Expression in Nasal Epithelium May Explain the Lower Prevalence of Pediatric Infections
    11. Children with COVID-19 May Present with Neurological Symptoms and Splenial Changes on Imaging
    12. Pediatric COVID-19 Case Series

  2. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19
    1. Multisystem Inflammatory Syndrome in Children: A Systematic Review
    2. CDC Case Tracker
    3. CDC Case Definition
      • Patients <21 years presenting with fever of >38.0°C for ≥24 hours or subjective fever ≥24 hours; AND
      • Laboratory evidence of inflammation including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, LDH, or IL-6, elevated neutrophils, reduced lymphocytes, and low albumin; AND
      • Evidence of clinically severe illness requiring hospitalization with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
      • No alternative plausible diagnoses; AND
      • Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
      • Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection.
    4. Guidance
    5. MIS-C Case Series and Reviews
    6. MIS-C Research (MIS-C Immunopathology Diagram)
    7. Multisystem Inflammatory Syndrome in Adults (MIS-A)
Share

Leave a Reply

Your email address will not be published. Required fields are marked *